These data suggest that activation of FGF signaling plays a role in resistance to a CDK4/6 inhibitor and ET against ER+ breast cancer and that tasurgratinib exhibits significant antitumor activity in combination with ET against ER+ breast cancer based on inhibition of the FGF signaling pathway. Here, CDK4 is linked to breast cancer.